| |
|
| |
| Links: |

PCA or patient-controlled analgesia pumps is a way with which analgesic can be self-administered by the patient as and when needed. Patient-controlled analgesia pumps are not used to treat long term pains. PCA is used in various applications such as oncology or chemo therapy, pediatrics, gastroenterology, hematology and diabetes. There are several benefits of using PCA. It allows complete control on the pain treatment. It also assists in preventing the formation of blood clots and promotes healing at a faster rate. However, there are certain disadvantages, the main aspect being an occurrence of an over dost or an under dose that can take place in case of improper settings and programming of the device. Government initiatives to boost home medication, rising awareness about patient-controlled analgesia pumps, and affordable costs are few of the aspects contributing to the expansion of patient-controlled analgesia pumps market at a global level.
The global patient-controlled analgesia pumps market is projected to grow at a high CAGR during the period of forecast and is estimated to reflect a valuation of above US$ 500 Mn by the end of the year of forecast.
Global Patient-Controlled Analgesia Pumps Market: Dynamics
The growth of the global patient-controlled analgesia pumps market is influenced by aspects such as various advantages of PCA system over conventional continuous infusion systems, increasing standardization for reducing costs in hospitals, development of quality indicators for patient-controlled analgesia pumps, modernization with a view to reduce errors, increasing adoption of PCA owing to increasing prevalence of cancer, pain and diabetes, rising forward integration and increasing demand for PCA in rental and homecare services. These factors have contributed to the growth of the global market. On the contrary, lack of skilled manpower and lack of standard usage guidelines and vast product recalls are hampering the growth of the global patient-controlled analgesia pumps market. Various trends have been observed, to name a few, rapid med-tech progress, shifting production base to emerging economies, user-friendly advanced equipment and fragmented market. Opportunities such as increasing production base for smart pumps with bigger drug libraries and expanding production base for PCA, ambulatory and other pumps have been boosting the growth of the global market.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5710
Segmental Highlights
The global patient-controlled analgesia pumps market has been segmented by product type, by end user, by application and by region.
By product type, the PCA pumps segment is estimated to be the largest segment in terms of market value and likely to lead the global market. it is also projected to grow at a higher pace thus reflecting high potential for growth of global market in the coming years
By region, Asia Pacific excluding Japan (APEJ) region is projected to be the fastest growing with a high 9.6% CAGR during the forecast period. North America is the largest from a market share perspective
By end user, hospitals segment is the most lucrative. This segment dominated the global market in 2017 and is expected to lead the market by 2026 end with a valuation of more than US$ 200 Mn
By application, diabetes segment is the fastest growing segment with a high CAGR of 6.0% throughout the period of forecast
Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5710
The research report has also profiled various leading players in the global patient-controlled analgesia pumps market. Companies like Becton Dickinson and Company, Baxter International, B.Braun Melsungen AG, Terumo Corporation, Ace Medical Co. Ltd., Micrel Medical Devices, Hospira (Pfizer Inc.), Fresenius Kabi Group and Smiths Group plc., have been profiled in this research report.

The research report titled “Orthobiologics Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” covers annual sales revenue generated by various market segments during the period of assessment 2017-2027. Furthermore, developments taking place in the market, various trends impacting the performance of the market and other drivers fuelling revenue growth of the global orthobiologics market are enumerated in this elaborate research study. Certain challenges that are pulling market growth southward are also assessed in this report. The report presents a high-level overview of the global orthobiologics market to the reader and extends support in planning future moves by portraying an accurate forecast model of the global orthobiologics market.
Global Orthobiologics Market: Key Forecast Highlights
The global orthobiologics market research report features the current market scenario as well as the future growth prospects. According to this study, the global orthobiologics market is projected to grow at a CAGR of 3.5% throughout the period of assessment 2017-2027. In 2017, the global orthobiologics market was valued at US$ 4.8 Bn and it is estimated to reach a valuation of more than US$ 6500 Mn by the end of the assessment year (2027).
Global Orthobiologics Market: Highlights on Different Segments
The global market for orthobiologics is segmented by product type, by end user and by region.
By region, North America is expected to be a highly lucrative market for orthobiologics. Several advancements in healthcare along with rising expenditure on research and development in this region are key parameters pushing the growth of the market upward. The orthobiologics market in North America is expected to reach a value over US$ 3 Bn by the end of the forecast period. The orthobiologics market in Asia Pacific excluding Japan (APEJ) is projected to rise at a higher CAGR of 4.4% during the period of forecast.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-786
By end user, the hospitals and ambulatory surgical centres segments are expected to grow at the same pace during the forecast period. However, with respect to revenue, hospitals are a more lucrative option for orthobiologics manufacturers as they have reflected higher demand over the last few years. Orthopaedic clinics are also expected to witness significant growth and register a CAGR of 3.6% during the period of assessment.
By product type, the bone graft stimulators segment is the largest and is estimated to reach a market valuation of more than US$ 3 Bn by the end of 2027. Viscosupplements segment is the second largest and a highly lucrative segment expected to witness a higher pace of growth during the forecast period.
Global Orthobiologics Market: Growth Influencing Factors
Factors such as rising incidence of orthopaedic disorders leading to fractures, increasing incidence of sports injuries, rising adoption of orthobiologics material, rising demand for out-patient surgical procedures, increasing demand for orthopaedic surgeries owing to medical tourism and rising technological developments to enhance surgery time and efficiency are supporting the growth of the global orthobiologics market. But the market is not void of challenges. High cost of orthopaedic surgery, increasing competition causing price fluctuations, lack of awareness, uncertainty about efficacy, availability of alternative therapies and issues related to devices are posing restraints to the growth of the global orthobiologics market.
Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-786
Global Orthobiologics Market: Competitive Assessment
The research report on the global orthobiologics market delivers a complete package of market intelligence by covering the analysis on participants in the market. Major companies profiled in this research report include Medtronic plc., NuVasive, Inc., Stryker Corporation, Zimmer Biomet Holdings, Orthofix International N.V., Anika Therapeutics, Inc., DePuy Synthes (Johnson & Johnson), Bioventus, Arthrex, Inc., SeaSpine Holdings Corporation, Sanofi-Aventis (Sanofi SA), Djo Global, Inc., Seikagaku Corporation, RTI Surgical, Inc., Heraeus Holding GmbH, Fidia Pharma USA Inc., TRB Chemedica International SA, Allosource, Musculoskeletal Transplant Foundation, Inc., and Ito Co., Ltd.
pop (Added: Thu Feb 28 2019 Hits: 135 Rating: 0.00 Votes: 0) Rate ItA new study by the company, titled ' Endometriosis Treatment Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028,' points out the key dynamics present in the endometriosis treatment market. Endometriosis is a very painful condition for women, mostly affecting women in the reproductive age group. The condition can stay beyond that age and can cause a lot of physical and emotional stress. At present, the endometriosis treatment market offers no such reliable laboratory test even though it is an absolute need. Currently, not a single endometriosis cure option is available. Hence, endometriosis treatment is basically a pain suppressing action. A large number of women are affected by this condition and endometriosis treatment leads to a high healthcare expenditure. Not everyone can afford such treatment, thus, leading to severe difficulties among patients. An estimated annual economic cost exceeding billions of dollar is lost, which is mainly due to the loss of productivity among the patients.
There is evidence that endometriosis may slightly increase a woman’s risk of developing a form of cancer. Preventive endometriosis treatments are present to reduce the risk of cancer among patients with endometriosis. However, the complete risk of developing ovarian cancer is low among patients and there is no hereditary characteristic related to endometriosis that could lead to cancer. Considering all this, there are some exceptions in types of ovarian cancer which are more observed in women with endometriosis conditions, though the percentage is minimum. Other situations are much worse, as late endometriosis treatment could lead to infertility in women. IVF complications are more in women with active endometriosis as per clinical studies and research. There are also chances of adverse pregnancy outcomes in women with endometriosis. As there are no such reliable laboratory tests or surgical diagnosis methods for endometriosis, it becomes hard for a patient to get early treatment.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3870
Understanding endometriosis treatment is still in shadows in most parts of the world. Women have to wait for a very long time for an accurate diagnosis of endometriosis. The symptoms associated with the condition are often ignored by medical professionals and are treated as normal pain suffered during menstruation. The unbearable pain suffered by women with endometriosis, affects every part of their lives. To change this scenario, more women and young girls need education about the endometriosis condition so that they can recognize the symptoms and undergo early endometriosis treatment. Companies are coming with major branding and marketing as well as new endometriosis treatment drugs with reduced costs to reach the actual number of people affected with endometriosis.

Oral contraceptives are a basic drug type used in endometriosis treatment. Patients are subjected to hormonal therapy endometriosis treatment which triggers hormonal activity in the woman’s body, lowering the hormones responsible for the menstrual cycle. New generation endometriosis treatments such as GnRH Analogues, are estimated to gain huge acceptance due to their quality response. Elagolix, brand name Orilissa, is a GnRH antagonist which recently got FDA approval. It is projected to mark a standard in endometriosis treatment. Manufacturers are focusing on hormonal therapy drugs for endometriosis treatment, as they work much more efficiently than most other pain management endometriosis treatment options. The rise in endometriosis cases and rising awareness have led to a number of new drugs being held under the research phase for endometriosis treatment.
Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-3870
The endometriosis treatment market is mostly consolidated in seven key regions. However, with a rise in awareness for endometriosis treatment, the market is estimated to hit other regions where the condition is still in shadows. Most of the drugs used for endometriosis treatment are off-label drugs, but clinical trials are being conducted for drugs that are primarily used for endometriosis treatment. Some of the key companies analyzed and studied in the endometriosis treatment market include AbbVie Inc., Bayer AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Ipsen Pharma, Myovant Sciences Ltd, Endoceutics, Inc., Debiopharm Group and Mayne Pharma Group Limited.
pop (Added: Wed Feb 27 2019 Hits: 122 Rating: 0.00 Votes: 0) Rate It
Pages: [<<] ... 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 ... [>>]
Links SQL By: Gossamer Threads Inc.